An Evolving Treatment Paradigm for Hepatocellular Carcinoma

An Evolving Treatment Paradigm for Hepatocellular Carcinoma

Episodes

Specialty:

All

Year:

All

EP. 1: Considerations for Biopsy in Diagnosing HCC

July 30th 2018

EP. 2: Noninvasive Methods for the Diagnosis of HCC

July 30th 2018

EP. 3: HCC Staging Systems Explored

July 30th 2018

EP. 4: Recognizing HCC Risk Factors

July 30th 2018

EP. 5: Challenges in Managing Newly Diagnosed Advanced HCC

July 30th 2018

EP. 6: Locoregional Therapies for Advanced HCC

July 30th 2018

EP. 7: Locoregional Versus Systemic Therapy for HCC

July 30th 2018

EP. 8: Liver-Directed Therapy +/- Sorafenib in HCC

July 30th 2018

EP. 9: Upfront Lenvatinib in Unresectable HCC

July 30th 2018

EP. 10: Practical Considerations for Using Lenvatinib in HCC

July 30th 2018

EP. 11: Appropriateness for Regorafenib in Metastatic HCC

July 30th 2018

EP. 12: Immunotherapy in Second-Line Metastatic HCC

July 30th 2018

EP. 13: Checkpoint Inhibitors Versus TKI Therapy in HCC

July 30th 2018

EP. 14: Multitargeted TKI Therapy in Metastatic HCC

July 30th 2018

EP. 15: Anti-VEGF Therapy in Metastatic HCC

July 30th 2018

EP. 16: Perspectives on the Future Treatment of HCC

July 30th 2018

Trending on OncLive

Osimertinib Plus Gefitinib Suppresses Acquired EGFR Resistance Mutations in First-Line NSCLC

AMIGO-1 Trial Meets 18-Month PFS End Point With Frontline Amivantamab Triplet in EGFR+ NSCLC

Bexobrutideg Produces High Response Rates Across Treatment Lines in CLL/SLL

FDA Accepts NDA for Bezuclastinib in Advanced Systemic Mastocytosis

FDA Grants Fast Track Designation to Cesalatamig in Immunotherapy-Pretreated NSCLC